Citations

Clear

7 citation(s) found for "Li, Linxin".

Biomarkers for myelin oligodendrocyte glycoprotein-associated disease: recent advances and future
Zheng, Qingying, Wen, Muzi, Zheng, Xinyi , Wen, Linxin , Cheng, Ruogu, Gao, Ye, Yuan, Chao , Shang, Pei , Wen, Muzi, Gao, Ye

Mayo Clinic

Frontiers in Immunology | July 31, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1807565 | PMID 42602431 Get It

MOGAD is a rare autoimmune encephalomyelitis that shares similar clinical manifestations with other central nervous system demyelinating diseases. However, they must be distinguished due to their distinct pathogenesis and treatment methods. Currently, the clinical diagnosis of MOGAD primarily relies on patients’ clinical manifestations and imaging features, with biomarker application being relatively limited. Meanwhile, research on MOGAD biomarkers has advanced rapidly, with findings mainly focusing on imaging features, antibody titers, nerve cell markers, cytokines, and inflammatory cell ratios. These biomarkers can distinguish among various autoimmune with similar clinical manifestations and exhibit certain specificity. If these biomarker findings are applied to the clinical diagnosis of MOGAD, they could enhance diagnostic accuracy and support earlier and more accurate diagnosis, while providing a scientific basis for evaluating disease progression and prognosis. We discuss the biomarkers and emerging biomarkers of MOGAD, emphasizing the specific changes and aspects that may be applicable to clinical diagnosis and treatment.
Epstein-Barr virus-associated multiple sclerosis: recent mechanistic advances and clinical therapeutic perspectives
Cheng, Ruogu, Y, Gao , Zheng, Ruoyi , Wen, Muzi, Li, Gaoling, Pan, Wenbin, Liao, Yuqiao, Wen, Linxin , Hu, Yueyang, Zhao-Fleming, Hannah , Shang, Pei , Wen, Muzi

Mayo Clinic

Frontiers in Immunology | May 21, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1799161 | PMID 42253989 Get It

Multiple sclerosis (MS) is an immune-mediated chronic inflammatory and degenerative disease of the central nervous system (CNS). Typically occurring in young and middle-aged individuals, untreated MS can have high rates of disability and recurrence, thereby imposing a significant burden on the patient, their family, and society. Many factors are implicated in the etiology of MS, with the relationship between Epstein-Barr Virus (EBV) infection and the development of MS being the subject of extensive research recently. When the human body experiences a decline in immune function, it may trigger reactivation of EBV, and this reactivation is also believed to increase the risk of onset or relapse of MS. Currently, the phenomenon of cross-reactivity resulting from molecular mimicry following EBV infection (including reactivation status) is theorized as a contributing etiology. EBV-mediated abnormalities in T cells and B cells also play a key role in the development of MS. However, the underlying mechanisms have not been thoroughly understood. Meanwhile, the limited availability of effective treatment options for MS, in particular MS progression, underscores the urgent need for novel therapeutic strategies. Here, we discuss the pathophysiological mechanisms underlying MS, specifically emphasizing the relationship between EBV infection and the disease pathology. Furthermore, we introduced relevant pharmacological targets in order to propose a broader range of therapeutic alternatives for individuals diagnosed with MS.
The potential of noninvasive brain stimulation techniques for the treatment of central nervous system demyelinating diseases: a narrative review
Shen, Yinan , Lin, Zhixuan, Wen, Linxin, Cheng, Ruogu, Shang, Pei , Shang, Pei , Lin, Zhixuan, Wen, Linxin

Mayo Clinic

Advanced Technology in Neuroscience | November 27, 2024 | Volume: 1 | Issue: 2 | Pages: 211-228

10.4103/atn.atn-d-24-00020 Get It

Noninvasive brain stimulation techniques have emerged as a promising therapeutic option for various central nervous system demyelinating diseases. Demyelinating diseases represent a group of pathological conditions that impact the central or peripheral nervous system. They are characterized by damage to or loss of the myelin sheath surrounding nerve fibers. This damage to myelin sheaths disrupts nerve signal transmission, leading to a wide range of signs and symptoms associated with neurological impairment. Treatment for demyelinating diseases usually aligns with the specific underlying cause. Noninvasive brain stimulation techniques can affect neuronal electrical activity and glial cell function, suggesting a potential option for intervention. In this narrative review, we explore the potential of noninvasive brain stimulation techniques for the treatment of central nervous system demyelinating disorders. Noninvasive brain stimulation techniques, including transcranial magnetic stimulation, transcranial electrical stimulation, transcranial focused ultrasound stimulation, optogenetic stimulation, low-intensity pulsed ultrasound, and transcranial photobiomodulation, have been shown to potentially intervene in the treatment of demyelinating diseases by affecting the electrical activity of nerve cells and glial cell function. In addition, this review summarizes the applications and mechanisms of noninvasive brain stimulation techniques in the treatment of central nervous system demyelinating diseases and how these techniques promote myelin regeneration and improve disease prognosis. This review also summarizes research advances in noninvasive brain stimulation techniques for the treatment of multiple sclerosis, acute disseminated encephalomyelitis, progressive multifocal leukoencephalopathy, and neuromyelitis optical spectrum disorder. Noninvasive brain stimulation techniques can improve disease symptoms by promoting oligodendrocyte proliferation and differentiation, enhancing myelin regeneration, and modulating immune responses. Although noninvasive brain stimulation techniques have shown potential in the treatment of various neurological disorders, their use in treating demyelinating diseases remains challenging. For example, transcranial focused ultrasound stimulation is a relatively new noninvasive brain stimulation technique with the advantages of high spatial resolution and the ability to stimulate deep brain structures, but its safety and efficacy in clinical applications need to be further investigated. Optogenetic stimulation offers highly precise neuromodulation, but its feasibility in clinical practice is limited by technical and ethical constraints. Overall, noninvasive brain stimulation techniques have significant potential in the treatment of central nervous system demyelinating diseases, but further research is needed to optimize stimulation parameters, improve therapeutic efficacy, and gain insight into their mechanism of action. With the continuous development of technology and in-depth clinical trials, noninvasive brain stimulation techniques are expected to become an effective treatment for central nervous system demyelinating diseases and provide new therapeutic options for such patients.
The applications of spinal cord stimulation in diseases with motor disorders, pain, and cognitive disturbance
Wen, Linxin, Zheng, Ruoyi , Cheng, Ruogu, Gao, Ye , Wen, Muzi, Shang, Pei , Wen, Linxin, Lin, Mingkai

Mayo Clinic

Advanced Technology in Neuroscience | November 7, 2024 | Volume: 1 | Issue: 1 | Pages: 2-17

10.4103/atn.atn-d-24-00001 Get It

Spinal cord stimulation (SCS), first used for pain relief in 1967, serves as an invasive neuromodulation with the targeted delivery of stimulations and the alertness of neural activities. Based on the gate-controlled theory of pain and multiple research studies, the application of SCS to motor recovery, pain relief, and sensory and cognitive restoration has been shown to be significant. Considering that movement disorders and pain are complications of various diseases, the categories, applications, and technical operation of SCS are coming of age. In terms of its impact on the immune system, SCS alters the trajectory of neurological diseases by modulating local immune responses through immunomodulatory mechanisms that vary depending on the different patterns of SCS. In addition to existing targets, the combinations of SCS and emerging techniques deepen the research at the molecular level, contributing to the exploration of potential targets and novel treatments. However, to secure a place in the future trend of non-invasive and precise treatment, it is necessary to improve SCS in terms of mechanism research, cost reduction, and application to more diseases.
Abstract 11: The Utility of Causative Classification System: Correlation between Causative and Phenotypic Stroke Subtypes
Barrett, Kevin M. , Biffi, Alessandro , Gamble, Dale M., Grazer, Anja, Gschwendtner, Andreas, Helenius, Johanna, Huq, Mohammed Saiful, Katschnig, Petra , Katsnelson, Michael , Kittner, Steven J. , Malik, Shaneela , Ossi, Raid G., Peddareddygari, Leema Reddy , Pucek, Mateusz, Saraf, Neha, Sheikh, Huma U., Stoegerer, Eva, Weissman, Darren, Woo, Daniel , Worrall, Bradford B. , Ay, Hakan , Arsava, Ethem Murat , Brenner, David A. , Brown, Robert , Huq, Mohammed, Li, Linxin , Labovitz, Daniel , Meschia, James F. , Rannikmäe, Kristiina , Rhodes, David , Southerland, Andrew M.

Mayo Clinic

Stroke | March 20, 2022 | Volume: 43 | Issue: suppl_1 | Pages: No page available

10.1161/str.43.suppl_1.a11 Get It

Background: Causative Classification of Stroke (CCS) system is a novel, web-based, and fully-computerized algorithm that integrates clinical, diagnostic, and etiologic stroke characteristics in an evidence-based manner (available at http://ccs.mgh.harvard.edu ) and provides in a given patient both phenotypic subtypes where abnormal evaluation findings are simply organized in major etiologic categories and causative subtypes where abnormal evaluation findings are filtered through a decision making process to identify the most likely cause of stroke. In this study, we sought to identify the concordance between phenotypic and causative CCS subtypes in the NINDS Stroke Genetics Network (SiGN). Methods: A total of 24 adjudicators from 15 US and European sites certified in CCS retrospectively determined CCS subtypes through chart review in 7134 patients. The CCS software provided causative subtypes in 3 confidence levels as “evident”, “probable” or “possible” based on the weight of causal evidence. We estimated how often CCS classified a given major abnormal evaluation finding as the causative stroke mechanism. Results: CCS assigned 55% of patients with the phenotype of moderate-to-severe atherosclerotic stenosis into the causative category of “evident large artery atherosclerosis”. Likewise, 50% of patients with a major cardiac source (such as atrial fibrillation) were classified into “evident cardio-aortic embolism”, and 74% of those with imaging evidence of a typical lacunar infarct into “evident small artery occlusion”. In 20% to 30% of patients, phenotypic and causative categories were the same but the causative subtype was assigned with a lower level of confidence. Six to 20% of patients with a given phenotypic feature were classified into a different causative category. Failure to investigate for other subtypes in the presence of a positive test finding and the presence of multiple competing etiologies were key contributors to the observed disconcordance between phenotypic and causative subtypes. Conclusions: Our findings show that the presence of a major abnormality in stroke evaluation does not necessarily mean that it is always the cause. The ability of CCS system to discriminate between phenotypic and causative characteristics of stroke etiology provides the opportunity to refine stroke phenotypes for use in research studies.
Pathogenic Ischemic Stroke Phenotypes in the NINDS-Stroke Genetics Network
Ay, Hakan , Arsava, Ethem Murat , Andsberg, Gunnar , Benner, Thomas, Brown, Robert D. , Chapman, Sherita , Delavaran, Hossein , Dichgans, Martin , Engström, Gunnar , Giralt‐Steinhauer, Eva , Grewal, Raji P., Gwinn, Katrina , Jiménez-Conde, Jordi , Katsnelson, Michael , Kissela, Brett , Kittner, Steven J. , Kleindorfer, Dawn , Labovitz, Daniel , Lanfranconi, Silvia , Lee, Jin‐Moo , Lehm, Manuel, Lemmens, Robin , Levi, Christopher , Li, Linxin , Lindgren, Arne, Markus, Hugh S. , McArdle, Patrick F. , Melander, Olle , Peddareddygari, Leema Reddy , Pedersén, Annie , Pera, Joanna , Rannikmäe, Kristiina , Rexrode, Kathryn M. , Rich, Stephen S. , Rothwell, Peter M. , Schmidt, Reinhold , Schürks, Markus , Seiler, Stephan , Słowik, Agnieszka , Sudlow, Cathie , Thijs, Vincent , Woodfield, Rebecca, Worrall, Bradford B. , Chapman, Sherita N, Cole, John W. , Giralt-Steinhauer, Eva, Jern, Christina, Jood, Katarina, Kleindorfer, Dawn O, Labovitz, Daniel L, Levi, Chris, Rhodes, David, Rundek, Tatjana , Slowik, Agnieszka, Jern, Christina , Jood, Katarina , Lindgren, Arne, Norrving, Bo , Rhodes, David , Roquer, Jaume , Rosand, Jonathan M. , Sacco, Ralph L. , Sharma, Pankaj Kumar , Meschia, James F. , Dichgans, Martin , Rich, Stephen S , Lemmens, Robin , Lee, Jin-Moo

Mayo Clinic

Stroke | November 7, 2014 | Volume: 45 | Issue: 12 | Pages: 3589-3596

10.1161/strokeaha.114.007362 | PMID 25378430 Get It

Background and Purpose— NINDS (National Institute of Neurological Disorders and Stroke)-SiGN (Stroke Genetics Network) is an international consortium of ischemic stroke studies that aims to generate high-quality phenotype data to identify the genetic basis of pathogenic stroke subtypes. This analysis characterizes the etiopathogenetic basis of ischemic stroke and reliability of stroke classification in the consortium. Methods— Fifty-two trained and certified adjudicators determined both phenotypic (abnormal test findings categorized in major pathogenic groups without weighting toward the most likely cause) and causative ischemic stroke subtypes in 16 954 subjects with imaging-confirmed ischemic stroke from 12 US studies and 11 studies from 8 European countries using the web-based Causative Classification of Stroke System. Classification reliability was assessed with blinded readjudication of 1509 randomly selected cases. Results— The distribution of pathogenic categories varied by study, age, sex, and race ( P <0.001 for each). Overall, only 40% to 54% of cases with a given major ischemic stroke pathogenesis (phenotypic subtype) were classified into the same final causative category with high confidence. There was good agreement for both causative (κ 0.72; 95% confidence interval, 0.69–0.75) and phenotypic classifications (κ 0.73; 95% confidence interval, 0.70–0.75). Conclusions— This study demonstrates that pathogenic subtypes can be determined with good reliability in studies that include investigators with different expertise and background, institutions with different stroke evaluation protocols and geographic location, and patient populations with different epidemiological characteristics. The discordance between phenotypic and causative stroke subtypes highlights the fact that the presence of an abnormality in a patient with stroke does not necessarily mean that it is the cause of stroke.
Stroke Genetics Network (SiGN) Study
Arnett, Donna K. , Ay, Hakan , Brown, Robert D. , Benavente, Oscar, Bakker, Paul I. W. de , Dichgans, Martin , Doheny, Kimberly F. , Fornage, Myriam , Grewal, Raji P., Gwinn, Katrina , Conde, Jordi Jiménez, Johnson, Julie A. , Laurie, Cathy C. , Lee, Jin‐Moo , Lindgren, Arne, Markus, Hugh S. , McArdle, Patrick F. , McClure, Leslie A. , Mitchell, Braxton D. , Schmidt, Reinhold , Rexrode, Kathryn M. , Rich, Stephen S. , Rothwell, Peter M. , Sacco, Ralph L., Shuldiner, Alan R. , Słowik, Agnieszka , Sudlow, Cathie , Thijs, Vincent , Woo, Daniel , Worrall, Bradford B. , Wu, Ona , Kittner, Steven J. , collaborators, The SiGN study also includes the following, Anderson, Christopher D. , Andrén, Kerstin , Barrett, Kevin M. , Benner, Thomas, Bentley, Paul , Bevan, Steven, Biffi, Alessandro , Chapman, Sherita , Cheng, Yu‐Ching, Delavaran, Hossein , Gamble, Dale M., Giralt, Eva, Grazer, Anja, Gschwendtner, Andreas, Hegge, Caityln, Heitsch, Laura , Helenius, Johanna, Huq, Mohammed Saiful, Irie, Robert E., Jackson, Rebecca D. , Katschnig, Petra , Katsnelson, Michael , Khoury, Naïm , Kilinc, Selma, Kumar, Gyanendra, Langefeld, Carl D. , Lemmens, Robin , Malik, Shaneela , Melander, Olle , Nordström, Sara , Ois, Ángel , Ossi, Raid G., Peddareddygari, Leema Reddy , Pedersén, Annie , Pucek, Mateusz, Redfors, Petra , Rhodes, J. , Saraf, Neha, Schuerks, Markus, Seiler, Stephan , Sheikh, Huma U., Sparks, Mary J., Stoegerer, Eva, Temple, Ella, Valenti, Raffaella , Weir, David R. , Weissman, Darren, Woodfield, Rebecca, Yiin, Gabriel , Soliman, Elsayed Z. , Cushman, Mary , Kumar, Gyanendra , Bevan, Steve , Meschia, James F. , Cole, John W. , Jern, Christina , Jood, Katarina , Lindgren, Arne, Rosand, Jonathan M. , Rundek, Tatjana , Sharma, Pankaj Kumar , Wassertheil-Smoller, Sylvia W , collaborators, The SiGN study also includes the following, Andsberg, Gunnar , Arsava, Ethem Murat , Bevan, Steven, Brenner, David A. , Deline, Chris A. , Dziedzic, Tomasz , Holmegaard, Lukas , Kilinc, Selma, Kumar, Gyanendra, Labovitz, Daniel , Lanfranconi, Silvia , Li, Linxin , Norrving, Bo , Pera, Joanna , Rannikmäe, Kristiina , Ribasés, Marta , Southerland, Andrew M. , Sunyer, Jordi , Dichgans, Martin , Rich, Stephen S , Lemmens, Robin , Mitchell, Braxton D , Shuldiner, Alan R , Arnett, Donna K , Wu, Ona , Lee, Jin-Moo

Mayo Clinic

Stroke | September 11, 2013 | Volume: 44 | Issue: 10 | Pages: 2694-2702

10.1161/strokeaha.113.001857 | PMID 24021684 Get It

Background and Purpose— Meta-analyses of extant genome-wide data illustrate the need to focus on subtypes of ischemic stroke for gene discovery. The National Institute of Neurological Disorders and Stroke SiGN (Stroke Genetics Network) contributes substantially to meta-analyses that focus on specific subtypes of stroke. Methods— The National Institute of Neurological Disorders and Stroke SiGN includes ischemic stroke cases from 24 genetic research centers: 13 from the United States and 11 from Europe. Investigators harmonize ischemic stroke phenotyping using the Web-based causative classification of stroke system, with data entered by trained and certified adjudicators at participating genetic research centers. Through the Center for Inherited Diseases Research, the Network plans to genotype 10 296 carefully phenotyped stroke cases using genome-wide single nucleotide polymorphism arrays and adds to these another 4253 previously genotyped cases, for a total of 14 549 cases. To maximize power for subtype analyses, the study allocates genotyping resources almost exclusively to cases. Publicly available studies provide most of the control genotypes. Center for Inherited Diseases Research–generated genotypes and corresponding phenotypes will be shared with the scientific community through the US National Center for Biotechnology Information database of Genotypes and Phenotypes, and brain MRI studies will be centrally archived. Conclusions— The Stroke Genetics Network, with its emphasis on careful and standardized phenotyping of ischemic stroke and stroke subtypes, provides an unprecedented opportunity to uncover genetic determinants of ischemic stroke.